Method and composition for modulating immune response
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10166281-B2
Publication Date
2019-01-01
Expiration Date
Abstract
Provided is a method for modulating an immune response which is not derived from alphavirus infection comprising administering to a subject in need thereof an effective amount of a composition comprising an alphavirus virus like particle.
Core Innovation
The invention relates to alphavirus virus like particles (VLPs) used for modulating an immune response. The alphavirus virus like particle comprises assembled viral structural proteins and does not contain a heterologous antigen, and it is described as not derived from alphavirus infection, supporting a use defined by composition rather than infection-derived material.
The problem addressed is the need to modulate an immune response against disease, including cancer. The approach is framed as immunomodulation in which administering an effective amount of a composition containing an alphavirus VLP enhances immune response activity relevant to cancer control and treatment or prophylaxis.
The documented composition options include alphavirus identities and corresponding structural protein options, including Chikungunya strains 37997 or LR2006 OPY-1 and Venezuelan equine encephalitis virus TC-83. The described approach includes therapeutic and prophylactic use for immune-related diseases, with an in vivo example indicating that CHIK VLP administration suppresses B16F10 tumor growth.
Claims Coverage
One independent claim is provided, focusing on immune response modulation against cancer by administering an effective amount of a composition comprising an alphavirus virus like particle that does not contain a heterologous antigen. The dependent claims refine the alphavirus identity and the specific viral structural proteins, and narrow the modulation to immune response enhancement against the cancer.
Modulating an immune response against a cancer with an alphavirus VLP lacking heterologous antigen
Administering, to a subject with a cancer, an effective amount of a composition comprising an alphavirus virus like particle, wherein said alphavirus virus like particle does not contain a heterologous antigen.
Immune response enhancement against the cancer
The modulation involves enhancing an immune response against the cancer.
VLP includes viral structural protein from defined alphavirus strains
The virus like particle includes a viral structural protein from one of the listed strains: Chikungunya strain OPY-1, Chikungunya strain 37997, or Venezuelan equine encephalitis virus TC-83 strain.
Alphavirus is Chikungunya virus
The method is specifically defined to use an alphavirus that is Chikungunya virus.
Structural protein strain restricted to OPY-1 or 37997
The method is carried out using a viral structural protein from either the Chikungunya strain OPY-1 or Chikungunya strain 37997 only.
Across the provided claims, immune modulation against cancer is achieved by administering an effective amount of an alphavirus virus like particle composition that lacks a heterologous antigen, with refinement to immune-response enhancement and restriction to specific alphavirus identities and viral structural protein strains, including Chikungunya OPY-1 or 37997 and Venezuelan equine encephalitis virus TC-83.
Stated Advantages
Modulates and enhances an immune response against a cancer.
Documented Applications
Modulating an immune response against a cancer by administering an effective amount of a composition comprising an alphavirus virus like particle.
Therapeutic and prophylactic use for immune-related diseases including cancer, with an example where CHIK VLP suppresses B16F10 tumor growth in mice.
Interested in licensing this patent?